DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The "Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Ventilator Associated Pneumonia (VAP) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

The report provides a snapshot of the pipeline development for the Ventilator Associated Pneumonia (VAP)The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Ventilator Associated Pneumonia (VAP)The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Ventilator Associated Pneumonia (VAP)The report also covers the dormant and discontinued pipeline projects related to Ventilator Associated Pneumonia (VAP)

Reasons to Buy

Establish comprehensive understanding of the pipeline activity across this Ventilator Associated Pneumonia (VAP) to formulate effective R&D strategiesGather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantageIdentify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicinePlot corrective measures for pipeline projects by understanding the pipeline depth and focus of Ventilator Associated Pneumonia (VAP) therapeuticsDevise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Topics Covered

1. Report Introduction

2. Ventilator Associated Pneumonia (VAP) Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Ventilator Associated Pneumonia (VAP)

4. Comparative Analysis

5. Products in Clinical Stage

Product DescriptionResearch and DevelopmentProduct Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment

Assessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type

8. Inactive Products

Product DescriptionResearch and DevelopmentProduct Development Activities

Companies Featured

Achaogen IncAdenium Biotech ApSAridis Pharmaceuticals LLCAstraZeneca PlcBayer AGCardeas Pharma CorpDestiny Pharma LtdDong-A Socio Holdings Co LtdLakewood-Amedex IncMedImmune LLCMeiji Seika Pharma Co LtdMerck & Co IncMotif Bio PlcNabriva Therapeutics AGPolyphor LtdShionogi & Co LtdTGV-Inhalonix IncThe Medicines CompanyTheravance Biopharma IncWockhardt LtdZavante Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jrkwgl/ventilator?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005213/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Infectious Diseases Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/01/2019 06:34 AM/DISC: 02/01/2019 06:34 AM


Copyright Business Wire 2019.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for Reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.